Androgens and prostate cancer risk

作者：Wiren Sara; Stattin Par^*

来源：Best Practice & Research Clinical Endocrinology & Metabolism, 2008, 22(4): 601-613.

DOI：10.1016/j.beem.2008.06.002

• prostatic neoplasms
• androgens
• finasteride
• testosterone
• late-onset hypogonadism
• testosterone replacement therapy

Androgens have been implicated in prostate tumourigenesis. However, no association between circulating levels of androgens and prostate cancer risk was found in a recent large pooled analysis of prospective studies. A decreased risk of prostate cancer among men treated with finasteride, a 5 alpha-reductase inhibitor which reduces levels of dihydrotestosterone, was observed in the Prostate Cancer Prevention Trial (PCPT), a large clinical trial. In the PCPT a higher number of high-grade tumours was found in the finasteride group than in the control group; the reason for this finding is still unclear. Treatment of symptoms of late-onset hypogonadism - such as decreased muscle and bone mass and decreased cognition and libido - has become more prevalent with the advent of new forms of administration of testosterone replacement therapy. One small placebo-controlled study showed no increase in incidence of prostate cancer after 6 months of testosterone therapy, but data on the safety of testosterone replacement therapy remain limited.

• 出版日期2008-8